Hyperfine maintained its 2026 revenue guidance of $20 million to $22 million and said it aims to submit a contrast agent to the FDA by the end of 2026, according to the company's second-quarter earnings call held August 6.
The portable MRI device maker first set the revenue target in May and has held it steady across two quarters of results. The contrast agent submission marks a potential expansion into ancillary products that could drive additional revenue per system once deployed in the field.
Hyperfine's core business centers on tabletop MRI systems designed for point-of-care imaging in settings where space and cost rule out traditional machines. The company has been shipping units since 2021 and counts hospitals and imaging centers across the United States among its customers. Revenue guidance of $20 million to $22 million implies modest growth from current quarter run rates, as the company scales manufacturing and expands its commercial footprint.
The contrast agent, a chemical compound administered to patients to improve MRI image clarity, requires its own regulatory pathway. The company said its contrast product study is 75 percent enrolled, placing it on track for FDA submission by December 2026. If approved, contrast sales would create a recurring revenue stream independent of equipment sales.
Hyperfine has held its revenue range steady across two earnings cycles while advancing a regulatory submission. The contrast submission timeline puts an FDA decision in early 2027 at the earliest, leaving 2026 revenue dependent on equipment placements and service revenue alone.
The contrast agent submission is the metric that decides whether Hyperfine enters an ancillary revenue stream in 2027. If the FDA accepts the submission by year-end 2026 and grants approval in the first half of 2027, the company gains a margin-accretive product line within its existing customer base.
